DEF 14A: Aspire Biopharma Seeks Reverse Split, Approves Note Issuance

Aspire Biopharma Holdings, Inc. calls a Special Meeting to vote on a reverse stock split to maintain Nasdaq listing and approve the issuance of shares from convertible promissory notes.

Summary

• A Special Meeting of Stockholders will be held on November 4, 2025, at 10:00 A.M. Eastern Time, to vote on three key proposals.
• Proposal 1 seeks to grant discretionary authority to the Board to effect a reverse stock split of common stock, with a ratio ranging from one-for-five (1-for-5) to one-for-forty (1-for-40), within one year of stockholder approval.
• The primary purpose of the reverse stock split is to regain compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share.
• Proposal 2 requests approval for the issuance of more than 19.99% of outstanding common stock upon the exercise of Convertible Promissory Notes, and the Floor Price (20% of the 5-day average closing price prior to the Closing Date) for conversion, as mandated by Nasdaq Rule 5635(d).
• On August 19, 2025, the Company issued Convertible Promissory Notes with an aggregate principal amount of $9,687,500 for a subscription price of $7,750,000, maturing on February 19, 2026.
• As of September 22, 2025, the outstanding balance of these Notes was $6,875,000, convertible into an estimated 73,588,712 shares of common stock at the current floor price.
• Proposal 3 seeks approval for one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies for the other two proposals.
• The record date for stockholders entitled to vote at the Special Meeting was September 10, 2025, with 49,525,970 shares of Common Stock outstanding.
• The Board unanimously recommends voting FOR all three proposals.

Sentiment

Score: 3

Explanation: The filing indicates significant challenges, including Nasdaq non-compliance and the need for a reverse stock split, which often signals underlying stock price weakness. While the convertible notes provide capital, they come with substantial dilution risk and a severe penalty for non-approval. The proposals are reactive measures to address existing problems rather than proactive growth initiatives, suggesting a negative sentiment.

Positives

• The reverse stock split aims to maintain Nasdaq listing, which is crucial for market visibility, investor confidence, and access to capital.
• An increased stock price resulting from a reverse split could improve marketability and liquidity, potentially attracting a broader range of institutional investors and analyst interest.
• Approval of the Notes Proposal prevents an event of default, avoiding the obligation to repay 120% of the outstanding principal ($6,875,000 plus accrued interest) in cash, thereby preserving working capital.
• The reverse stock split would create additional unreserved authorized shares, providing flexibility for future capital raises, strategic relationships, equity incentives, and acquisitions without immediate further stockholder approval (subject to certain rules).

Negatives

• The reverse stock split may not guarantee a sustained increase in stock price or long-term compliance with Nasdaq's minimum bid price requirement.
• The reverse stock split could decrease the liquidity of common stock due to a reduced number of outstanding shares.
• The issuance of shares from convertible notes will have a dilutive effect on existing stockholders' voting power and economic rights.
• Failure to approve the Notes Proposal could lead to an event of default, requiring the Company to pay 120% of the outstanding principal ($6,875,000) plus accrued interest in cash, potentially severely impacting business plans and requiring additional financing.
• The company received a Nasdaq deficiency letter on April 16, 2026, regarding non-compliance with the minimum bid price rule (Rule 5450(a)(1)).

Risks

• Uncertainty that the reverse stock split will increase the stock price sufficiently or maintain Nasdaq compliance for a sustained period.
• Risk of delisting from Nasdaq if other continued listing requirements (e.g., minimum stockholders' equity, public float, market value of public float, round lot holders) are not met, even if the bid price is compliant.
• Decreased liquidity of common stock post-reverse split due to fewer outstanding shares.
• Potential anti-takeover effect from an increased proportion of authorized but unissued shares, allowing for dilutive issuances that could prevent changes in Board composition or make tender offers more difficult.
• Dilution of existing stockholders' ownership and voting power from the issuance of shares upon conversion of the Convertible Promissory Notes.
• Potential decline in stock price or greater price volatility due to the issuance of additional securities from the convertible notes.
• Risk of an event of default under the Convertible Promissory Notes if the Notes Proposal is not approved, obligating the Company to repay 120% of the outstanding principal ($6,875,000) plus accrued interest in cash.
• Requirement to hold additional Special Meetings every 60 days if the Notes Proposal is not approved, incurring additional resource costs and diverting management attention.
• Adverse impact on future operating results and business plans if the Company is required to repay the Notes in cash due to insufficient capital.

Future Outlook

The company anticipates that a reverse stock split could increase its bid price to regain Nasdaq compliance and improve marketability. It also expects to use additional authorized shares for future capital raising, strategic relationships, equity incentives, and acquisitions. Failure to approve the Notes Proposal would adversely impact future operating results and business plans, potentially requiring additional financing.

Management Comments

• "The Board believes that enabling the Board to fix the specific ratio of the Reverse Stock Split within the stated range will provide us with the flexibility to implement it in a manner designed to maximize the anticipated benefits for our stockholders."
• "The Board believes that the Reverse Stock Split could increase the bid price of its Common Stock in order to gain compliance with Rule 5450(a)(1)."
• "The Board believes that the Reverse Stock Split could also improve the marketability and liquidity of the Common Stock."
• "We believe that the availability of the additional shares of Common Stock will provide us with the flexibility to meet business needs as they arise, to take advantage of favorable opportunities and to respond effectively in a changing corporate environment."

Industry Context

The biopharma industry often requires significant capital for research, development, and operations, making access to public markets and investor confidence crucial. Companies with low stock prices frequently face challenges in attracting institutional investment and analyst coverage, leading to reverse stock splits as a common strategy to address minimum bid price requirements and improve market perception. The issuance of convertible notes is a typical financing mechanism for growth-stage or capital-intensive companies, reflecting ongoing capital needs within the sector.

Comparison to Industry Standards

• Many small-cap biopharma companies face challenges in maintaining Nasdaq listing requirements, particularly the minimum bid price, leading to similar reverse stock split proposals.
• The issuance of convertible notes is a common financing mechanism for growth-stage or capital-intensive companies in the biopharma sector, but the dilutive effect and potential for default if shareholder approval is not obtained are standard considerations.
• The proposed 1-for-5 to 1-for-40 reverse split ratio is a broad range, typical for companies seeking flexibility to achieve a target price while minimizing the impact on share count and allowing for strategic adjustments based on market conditions.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased stock price and marketability post-reverse split, but also risk of decreased liquidity and significant dilution from convertible note conversions. Voting power will be diluted by note conversions.
• Convertible Note Holders: Will receive shares upon conversion, subject to a 4.99% (or up to 9.99%) beneficial ownership blocker. Protected by a 120% repayment clause in case of default if the Notes Proposal is not approved.
• Nasdaq: The company's ability to maintain its listing on the Nasdaq Capital Market is directly impacted by the outcome of the reverse stock split proposal.

Next Steps

• Hold a Special Meeting of Stockholders on November 4, 2025, to vote on the Reverse Stock Split Proposal, the Notes Proposal, and the Adjournment Proposal.
• If the Reverse Stock Split Proposal is approved, the Board will determine the specific reverse stock split ratio (within 1-for-5 to 1-for-40) and effect it within one year.
• If the Notes Proposal is not approved, the Company will be required to hold additional Special Meetings at least once every sixty (60) days until such stockholder approval is obtained.
• If the Notes Proposal is not approved, the Company may face an event of default under the Convertible Promissory Notes, obligating it to repay 120% of the outstanding principal plus accrued interest in cash.

Key Dates

Recommendation

The company is addressing critical issues (Nasdaq compliance, financing) that could lead to delisting or severe financial strain if not resolved. While the reverse stock split and note approval are necessary defensive actions, they also highlight underlying weaknesses in the company's market valuation and financial position. The potential for significant dilution from the convertible notes and the uncertainty of the reverse split's long-term impact on stock price suggest a 'hold' position, awaiting clearer signs of operational improvement and sustained market confidence beyond these immediate structural adjustments.

Keywords

Aspire Biopharma Holdings, ASBP, SEC filing, DEF 14A, proxy statement, reverse stock split, convertible notes, Nasdaq listing, stock dilution, corporate governance, shareholder meeting, capital raise, financial reporting, biopharma